{"name":"Neurosterix","slug":"neurosterix","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"NTX-253","genericName":"NTX-253","slug":"ntx-253","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"NTX-253","genericName":"NTX-253","slug":"ntx-253","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-01-09","type":"trial","source":"Indian Pharma Post","summary":"Addex spin-out Neurosterix launches Phase 1 trial for novel schizophrenia drug - Indian Pharma Post","headline":"Addex spin-out Neurosterix launches Phase 1 trial for novel schizophrenia drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE5NV1c1VHpVdzlINVBlRnZ6blJ6T3ZPT2lqSjItYmR0QUtVN0lUM0NnUGZ1MHVJTUFqaTdCdDh1Q0M1NHNNMmg0b21rVGI4VU9mNHFyd1RVOWE1U0hmRkw3anNXcWlwRGpm?oc=5","date":"2025-01-01","type":"earnings","source":"Switzerland Global Enterprise (S-GE)","summary":"Swiss biotech achieves record revenues in 2023 - Switzerland Global Enterprise (S-GE)","headline":"Swiss biotech achieves record revenues in 2023 - Switzerland Global Enterprise (S-GE)","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOLXlVUFdjNHhYUFVWYzJZbHRxVWxoQ2k0ZTdDdXlpZ24xb2tTWGNHQUJQR2NuX2N4d2lXYnhBMW9sUnJxWk5lUXlZWUpVZVoxcFlFaGl5SEM3M21rRkMzcVUwTC1oOUlUZFJCcGFkbXZjMTIxcExiY29STDNyYXd3Mm9FaWZqNnM3aTNCUUJmUUY1RDRpbEFzc21Xc3NVNFNEaGhXRVRsc1BkSlhicDJIZGthd19CQi1k?oc=5","date":"2024-07-26","type":"pipeline","source":"EU-Startups","summary":"Leading innovation: 10 promising European startups focusing on biopharmaceuticals - EU-Startups","headline":"Leading innovation: 10 promising European startups focusing on biopharmaceuticals - EU","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPdTlfRy1HNVM3a1Y4U2RYTjExWWs2Rkp5OXZTZ04yOFhwZ0thcC0xWlBOTHp4Y05QRTNQZUxUWjVUdE9zZG43YVdlZGlxUFNOeHExQWJrODZzWXlHRGxnZkhCZHJOdFpkQklWSnFDM1FCOWZUamVReFFKN3FYM3R2b3d5N3Nuc3cxVXhiZFBZTG9XYlg5TU9qRnBkb0Q4bVNKSzN1dHk4TFlrY3ctVzlJcVY1aEZCNUoyY1paVThlY2w1WEowZXc?oc=5","date":"2024-04-04","type":"pipeline","source":"Pharmaceutical Technology","summary":"Addex spinoff Neurosterix debuts with $63m for developing neurological therapies - Pharmaceutical Technology","headline":"Addex spinoff Neurosterix debuts with $63m for developing neurological therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxPWmdrb3lPRmpGRGFoYTNVZzVJVWpjWV9BN1BjSUpEY1BpYUs2cVItY2hkYmI1cGtJOWZjdW5FOWhEYnZqRlVXWUt2d0k4VGRiRHoxeGMyQ2hjZ3lvVmk5ZDhHaC16SlpfTldybmQ4VG1MWm1pNmVHV1ZrQnIzVzhSbXVkVXBKbVo3OFVHTG9CR1RKSTg0X1FVenRldS1rQ0h2TGkwT0VkUXdYVkJLQ091WVhLdjRuTFRtUUFZQ1NWR1BGclRfY2tNbld2ZmViYzBhandMcFYwa1JaQ3QzNF84aWljeFhtVzU2ZEdwUE5vNi1DWWs?oc=5","date":"2024-04-03","type":"pipeline","source":"Business Wire","summary":"Neurosterix launches with $63M to Advance Allosteric Modulator Therapeutics for Neurological Disorders - Business Wire","headline":"Neurosterix launches with $63M to Advance Allosteric Modulator Therapeutics for Neurological Disorders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNbWZRWnFpaGc3VUROblhsdHh5WkdlYS15X0V1RGhQSUx0R0FLbFRZRnU3bHotTzF1YktVNU05Ml9KSjBSRmM0VE5xaEVXemJCREpfS1Z0aDlUMTZtazYwRlNvVmZtLUoxdHJ1VWxaREJnblhCMVFwTmVWbEF2UU5RQi1odHJIV2xRb095MUtJVGZ0ZGJOZ1VNUzhR?oc=5","date":"2024-04-03","type":"pipeline","source":"Contract Pharma","summary":"Neurosterix Launches with $63M Series A Financing - Contract Pharma","headline":"Neurosterix Launches with $63M Series A Financing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOdVRaVW93UUdpY2NXZnptTkJLb1kyVXNkOXBTUkMtVURqSjg5dUJ6Mk13cnlONDRtc1FYMmpiUFR5Z09NOFRsc0hDYUhSSmlyNktZZjE0dDB3cFlVMWxJZ1JYR1B2ZTFCbkg2OFBHMWcxYmd5Rk4zUWxReFRaU0dkbA?oc=5","date":"2024-04-03","type":"pipeline","source":"pharmaphorum","summary":"Neurosterix emerges with $63m for neuroscience pipeline - pharmaphorum","headline":"Neurosterix emerges with $63m for neuroscience pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgJBVV95cUxQOTF6b09wWXlBT0VMc1JrNEd3LTRLb0o4NlVsSVI0UmVwVF8zeUxtS09ZamNONkJmMDhYVFVLSXh3V2l0N19BQlJYR1pWbnhVTEd3Rzk4bVYwSFRzSVprcmxvWWpCUTlldnNSTGlsMmE2cjBDQ3JXbzNSX09kUVZlNTdXUXFDZUxsX2JUdS1ROUNtMklveW1tbHhRVGFNZzA2TjlVbnBJbjVhX3I2UVZ5UHBSdjVmSXZtRTZvRGlMc1B0dmRRVndrblpOcDMxOUdENW1sZUl5aXgxMkU3MkpwemdieExvN29BMnVfQUZrUXlsWkZ2M015bm9wbmxBdk1sSm5ELVlpb2c1SDVCbk9MWGRGaFZmV1JPR1lFMkRJdVhqb2FmQWFHUzlOQ2VwQmRqSDV4NU9zS1VqQnR6OHc?oc=5","date":"2024-04-03","type":"pipeline","source":"GlobeNewswire","summary":"Addex and Perceptive Launch Neurosterix with $63 Million to - GlobeNewswire","headline":"Addex and Perceptive Launch Neurosterix with $63 Million to","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}